{
  "abstract": "An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more likely to have adverse kidney outcomes and reduced response to therapy. 1 2 Early response to therapy increases renal survival, with a modified primary efficacy response (mPERR) at 2 years, associated with up to a 75% and 67% reduced risk of impaired kidney function, end-stage kidney disease (ESKD) and death, respectively.1 Little is known of the clinical and pathological associates of kidney outcomes and response rates in the Anglo-Caribbean, a region with a high prevalence of SLE. We aimed to describe the response rates and outcomes in a cohort of lupus nephritis in Jamaica.",
  "authors": [
    {
      "affiliations": [
        "The University of the West Indies Caribbean Institute for Health Research, Kingston, Jamaica"
      ],
      "name": "Lori Ann Fisher"
    },
    {
      "affiliations": [
        "Department of Medicine, The University of the West Indies, Kingston, Jamaica",
        "Medicine, University of California Los Angeles, Los Angeles, California, USA"
      ],
      "name": "Joel Wright"
    },
    {
      "affiliations": [
        "Department of Pathology, The University of the West Indies, Kingston, Jamaica"
      ],
      "name": "Mahiri Bromfield"
    },
    {
      "affiliations": [
        "Department of Child Health, The University of the West Indies, Kingston, Jamaica"
      ],
      "name": "Rebecca Thomas-Chen"
    }
  ],
  "title": "Association of modified primary efficacy response rates at 1 year and outcomes in a cohort of lupus nephritis in Jamaica",
  "uid": "e50238d5-50f7-52f4-a155-f70e9fbdae71"
}